Alps Advisors Inc. Decreases Stock Position in Stryker Corporation $SYK

Alps Advisors Inc. decreased its position in shares of Stryker Corporation (NYSE:SYK) by 54.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,012 shares of the medical technology company’s stock after selling 3,622 shares during the period. Alps Advisors Inc.’s holdings in Stryker were worth $1,113,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Canada Post Corp Registered Pension Plan increased its holdings in shares of Stryker by 3.5% in the 3rd quarter. Canada Post Corp Registered Pension Plan now owns 13,960 shares of the medical technology company’s stock valued at $5,164,000 after acquiring an additional 471 shares during the last quarter. Appleton Partners Inc. MA increased its stake in Stryker by 2.5% during the third quarter. Appleton Partners Inc. MA now owns 30,254 shares of the medical technology company’s stock valued at $11,184,000 after purchasing an additional 745 shares during the last quarter. Concord Wealth Partners raised its holdings in shares of Stryker by 7.1% during the third quarter. Concord Wealth Partners now owns 1,035 shares of the medical technology company’s stock worth $383,000 after purchasing an additional 69 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of Stryker by 7.7% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 20,494 shares of the medical technology company’s stock worth $7,576,000 after buying an additional 1,460 shares during the last quarter. Finally, Black Diamond Financial LLC boosted its holdings in shares of Stryker by 12.8% in the 3rd quarter. Black Diamond Financial LLC now owns 1,968 shares of the medical technology company’s stock valued at $728,000 after buying an additional 224 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 252,118 shares of company stock valued at $91,504,172 in the last 90 days. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the topic of several research reports. TD Cowen lowered shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research note on Monday, January 26th. Wells Fargo & Company increased their price objective on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Robert W. Baird set a $437.00 target price on shares of Stryker in a report on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $426.94.

Stryker Stock Performance

SYK opened at $363.76 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $357.92 and its two-hundred day moving average price is $369.84. The firm has a market capitalization of $139.11 billion, a P/E ratio of 43.30, a price-to-earnings-growth ratio of 2.11 and a beta of 0.87. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the prior year, the business earned $4.01 earnings per share. Stryker’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is currently 41.90%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.